Antisecretory Factor Glioblastoma Phase 2
Antisecretory Factor During Concomitant and Adjuvant Therapy of Primary Glioblastoma, a Randomised, Prospective and Double Blinded Study
Peter Siesjö
300 participants
Jan 15, 2024
INTERVENTIONAL
Conditions
Summary
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis
Eligibility
Inclusion Criteria5
- Pathology verified glioblastoma or astrocytoma grade 4
- Age 18-75 years
- Surgical treatment-resection.
- Scheduled concomitant radiochemotherapy, or only chemotherapy.
- Informed consent
Exclusion Criteria4
- No informed consent
- Egg yolk allergy
- Only surgical biopsy
- Only radiotherapy
Interventions
Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
Egg yolk powder derived from hen fed with normal feed.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05669820